The application of transarterial chemoembolisation (TACE) with drug-eluting beads in patients with hepatocellular carcinoma and its response to the treatment will be observed. The registry has the following objectives: To assess the response to the treatment by standard methods and volumetric analysis as well as trying to determine any predictive response factors To determinate interobserver variability of the methods.
The patients with hepatocellular carcinoma in stage suitable for treatment by transarterial chemoembolization (TACE) with drug-eluting beads are included in the study. The investigators assess the response to the treatment by standard methods (RECIST, mRECIST) as well as by volumetric analysis. The size of tumor is evaluated on CT/MRI by two investigators prior to first TACE and then on all the check-ups (routinely every three months) until 31 December, 2019 or the patients' death.
Study Type
OBSERVATIONAL
Enrollment
61
A contrast agent (Xenetix350, Guerbet, France) was applied under local anaesthesia via the common femoral artery using a 5F sheath. Selective catheterization of the coeliac trunk and other arteries supplying the liver was then performed under fluoroscopic control. A pathological vascularization pattern was identified and chemoembolization material consisting of DC beads (BTG International Ltd) was injected by the treating angiographist using micro instrumentation. Follow-up CT or MRI was performed after 1-3 TACE sessions according to the extent of the lesion, 3 weeks following the last procedure. Patients with completed treatments were scheduled for an imaging follow-up every 3 months, allowing evaluation of the effect of treatment. In case of a positive response to the treatment another session of TACE was indicated. Chemoembolization sessions were performed as inpatient procedures with the mean hospitalization time of 4 days.
Predictive factors for overall survival and progression-free survival
RECIST, mRECIST, volumetric analysis
Time frame: 4 years 11 months
Interobserver variability of the methods used for assessing tumor response to the treatment
RECIST, mRECIST, volumetric analysis
Time frame: 4 years 11 months
Time from observation until death due to any cause (or censoring)
Overall survival
Time frame: 4 years 11 months
Time from observation until disease progression or death
Progression-free survival
Time frame: 4 years 11 months
Response to the treatment, as assessed by RECIST (v.1.1)
Objective Tumour Response will be assessed by the investigators on CT/MRI image analysis
Time frame: 4 years 11 months
Response to the treatment, as assessed by mRECIST
Objective Tumour Response will be assessed by the investigators on CT/MRI image analysis
Time frame: 4 years 11 months
Response to the treatment, as assessed by volumetric analysis
Objective Tumour Response will be assessed by the investigators on CT/MRI image
Time frame: 4 years 11 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.